С 8 по 10 декабря 2010 года в Эдинбурге прошла конференция “Drug Delivery to the Lungs –DDL 21”, в работе которой принимал участие генеральный директор ОАО «Фармацевтическая фабрика Санкт-Петербурга» Балаев Т.А.
Программа конференции:
Session 1:
Probing in vivo drug delivery - potential applications to bio-equivalence
Development of Idealized Throat Replicas for Inhaler Testing
Warren H. Finlay, University of Alberta
The highs and lows of pharmacokinetics in determining the equivalence of inhaled medicinal products
Professor Glyn Taylor, Welsh School of Pharmacy, Cardiff University
Utilizing In Vivo Lung Imaging Techniques to Assess Pulmonary Drug Delivery
Professor Beth, L. Laube, The Johns Hopkins University School of Medicine, Baltimore, Maryland USA
Regulatory Perspective on Bioequivalence Studies for Inhaled Products
Dr S Dissayanake, Mundipharma Research Ltd
A system for efficient and dose-controlled delivery of liquid substances to in vitro cell models of the lung epithelium
Dr Otmar Schmid, Comprehensive Pneumlogy Center, Institute of Lung Biology and Disease, Germany
Application of a Respiratory PBPK Model for Simulating Pulmonary Administration of Fluticasone Propionate in Humans
Dr S Ray Chaudhuri, Simulations Plus, Inc
Exhibitor Drinks Reception
sponsored by Vectura Group plc
Thursday 9th December 2010 - AM
Nebulisers: From jets to meshes
Dr Stephen Newman, Scientific Consultant, UK
Session 2:
Advances in formulation and analytical science
Ventilator Aerosol Delivery System (VADS): Concept for Rapid Delivery of Aerosolized Bronchodilators to Adult Patients on Mechanical Ventilation
Dr Jolyon Mitchell, Trudell Medical International, Canada
Electrostatic charge: we can measure it but does it really influence dry powder inhalation formulations
Dr Daniela Traini, Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Australia
The use of NMR in pMDI Development
Dr Dave Martin, AstraZeneca, UK
Widening the lens: Re-evaluating the Influence of Size and Morphology of DPI Carrier Particle Performance
Assistant Professor Hugh Smyth, Ph.D., College of Pharmacy, The University of Texas at Austin, USA
Novel Engineered Particle Formulation For Inhaled PYY(3-36) and Demonstration of Appetite Suppression In A Mouse Model
Mr D Vodak, Bend Research Inc, Oregon USA
What on Earth
Singing For BreathingTM - Effects of singing lessons in patients with COPD A Randomised Control Trial
Victoria Lord, Specialist Physiotherapist, Royal Brompton & Harefield NHS Foundation Trust, UK
Thursday 9th December 2010 – PM
Session 3:
The Pat Burnell New Investigator Award
Effect of lactose fines on fluidization properties and in vitro performance of Handihaler
Hanne Kinnunen, University of Bath, UK
Optimisation of Dry Powder Inhalers through Robust CFD Simulation of Air Classifiers
Sean Cheng, University of Cambridge
Surface modification of mannitol inhaler carrier particles via spray drying
Eva Littringer, Research Center Pharmaceutical Engineering GmbH, Austria
Comparison of in vitro methods to determine nasal versus lung deposition of a protein formulation
Regina Scherliess, Christian Albrecht University, Germany
Evaluation and modelling of the aerosolisation and break-up of agglomerated systems in dry powder inhalers
William Wong, University of Sydney, Australia
Ultrafast Analysis of Pressurised Metered Dose Inhaler (pMDI) by Direct Spray Mass Spectrometry (Direct Spray-MS)
Hitesh Raghvani, University of London, UK
What on Earth
Pioneers of Inhalation II; French kisses and steamy salons!
Mark Sanders, www.Inhalatorium.com, UK
Session 4:
Exploring the World of Dry Powder Inhalers
Non-destructive examination of inhalation blisters using X-ray computed micro-tomography
K. Lien Nguyen, GlaxoSmithKline, UK
What factors dominate the performance of conventional dry powder inhalation formulations?
Associate Professor Paul M Young, Advanced Drug Delivery Group, Faculty of Pharmacy, University of Sydney, Australia
Direct observation of particle dispersion mechanisms in DPI using particle image velocimetry technique
Xiang Kou, Dr. M. Teresa Carvajal, et al., Purdue University, USA
Engineering of Dry Powder Inhaler Formulation: The Colloidal Science Approach
Jag Shur, University of Bath, UK
Poster Drinks Reception
sponsored by The Technology Partnership
Friday 10th December 2010
Succeeding with Asthma
Karen Pickering, MBE, Asthma UK Ambassador
Session 5:
Increasing chances of success in early inhaled developments
How does Airflow Resistance Affect Inspiratory Characteristics as a Child grows into an Adult?
Mr D Harris, Sagentia Ltd, UK
Inhaled nanoparticle toxicity assay optimization: dose, size and oxidative potential
Abhinav Kumar, King’s College London, UK
What on Earth
Mucociliary Transport & the “Unusually Thick” Paradox
Mr R Hall, Mucokinetica Limited, UK
Beyond FEV1 - Assessing the airways"
Dr. Omar S Usmani, MBBS MRCP FHEA PhD, Clinical Senior Lecturer & Consultant Physician, National Heart and Lung Institute, Imperial College London & Royal Brompton Hospital
The development of a new rapid screening test for evaluating the non-stick performance of MDI canisters
P A Jinks, 3M Drug Delivery Systems, UK
Monitoring Systems for Inhaled Medication
Mr Tony Dyche, Respironics Respiratory Drug Delivery (UK) Ltd, UK
Collaborative efforts to understand the fate of drugs delivered to the lungs
Dr Ben Forbes, King’s College London